<DOC>
	<DOCNO>NCT00650793</DOCNO>
	<brief_summary>The purpose study Open Label Extension complete study evaluate efficacy safety 3 fix dosage Extended Release OROSÂ® Paliperidone</brief_summary>
	<brief_title>A 52-week , Open-label Extension Study Following 6-week , Double-blind , Placebo- Active- Controlled Study ( R076477-SCH-303 ) Evaluate Safety Tolerability Paliperidone ER Subjects With Schizophrenia</brief_title>
	<detailed_description>This 52-week , open-label extension study follow 6-week , double-blind , placebo- active-controlled study ( R076477-SCH-303 ) conduct 52 site 11 country . The primary objective open-label extension long-term assessment safety tolerability flexibly-dosed ER OROS® paliperidone . The secondary objective assessment long-term efficacy express function change total Positive Negative Syndrome Scale ( PANSS ) score , effect positive negative symptom schizophrenia mean change PANSS factor score , personal social functioning , overall functioning , quality life parameter measure Personal Social Performance Scale ( PSP ) , Clinical Global Impression Scale - Severity ( CGI-S ) , Schizophrenia Quality Life Scale ( SQLS ) , respectively . Subjects open-label phase receive flexibly dose ER OROS® paliperidone ( 3 mg 12 mg/day ) 52 week</detailed_description>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Paliperidone Palmitate</mesh_term>
	<criteria>Subjects complete doubleblind phase discontinue due lack efficacy least 21 day treatment , sign informed consent openlabel phase , investigator agree openlabel treatment best interest subject , eligible participate openlabel phase . Not eligible enter openlabel phase believe significant risk suicidal violent behavior openlabel extension trial , pregnant , received injection depot antipsychotic since entry precede doubleblind phase</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2010</verification_date>
	<keyword>Schizophrenia</keyword>
	<keyword>paliperidone</keyword>
</DOC>